Your browser doesn't support javascript.
The development of a home-based therapeutic platform for multiple myeloma.
Beer, Hayley; Routledge, David; Joyce, Trish; Furphy, Emma-Jane; Combe, Nella; Ritchie, David; Khot, Amit; Lim, Seok Ming; Montalto, Michael; Harrison, Simon J.
  • Beer H; Department of Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Australia.
  • Routledge D; Department of Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Australia.
  • Joyce T; Sir Peter MacCallum Department of Oncology, Melbourne University, Parkville, Australia.
  • Furphy EJ; Department of Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Australia.
  • Combe N; Department of Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Australia.
  • Ritchie D; Department of Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Australia.
  • Khot A; Department of Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Australia.
  • Lim SM; Sir Peter MacCallum Department of Oncology, Melbourne University, Parkville, Australia.
  • Montalto M; Department of Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Australia.
  • Harrison SJ; Sir Peter MacCallum Department of Oncology, Melbourne University, Parkville, Australia.
Expert Rev Hematol ; 14(12): 1129-1135, 2021 12.
Article in English | MEDLINE | ID: covidwho-1577548
ABSTRACT

BACKGROUND:

Multiple Myeloma (MM) accounts for 1-2% of all malignancies but is the second most common hematological malignancy. It is characterized by a proliferation of malignant plasma cells. The treatment paradigm of MM in Australia is traditionally hospital-based, complex, and costly. While MM comprises 1-2% of cancer diagnoses, it appears in the top 10 cancer diagnoses requiring hospital admission. The cumulative time spent receiving treatment is a significant burden for patients. The ability to receive treatment at home and maximize time away from hospital-based settings is a key preference for patients receiving anticancer therapies over a prolonged period of time.

METHODS:

The Peter MacCallum Cancer Centre and Royal Melbourne Hospital's combined Clinical Hematology Unit has collaborated with their Hospital in the Home departments to develop several innovative programs to address this.

RESULTS:

We describe our current active programs and potential developments in home-based MM therapy.

CONCLUSION:

We have enabled large numbers of patients to receive complex therapies in their own home and the COVID-19 pandemic has increased the pace of the roll out without any compromise in safety. We anticipate that the next raft of immunotherapies will be able to transition into the @Home treatment setting in the coming years.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 / Multiple Myeloma Type of study: Prognostic study Limits: Humans Language: English Journal: Expert Rev Hematol Journal subject: Hematology Year: 2021 Document Type: Article Affiliation country: 17474086.2021.2022471

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 / Multiple Myeloma Type of study: Prognostic study Limits: Humans Language: English Journal: Expert Rev Hematol Journal subject: Hematology Year: 2021 Document Type: Article Affiliation country: 17474086.2021.2022471